Journal of Nuclear Medicine
WEBThe Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and ...
SNMMI Annual Meeting Abstracts | Journal of Nuclear Medicine
WEBMeeting abstracts are available online. Follow the links below to search for specific abstracts presented at each meeting. 2024, Volume 65, Supplement_2. 2023, Volume 64, Supplement_1. 2022, Volume 63, Supplement_2. 2021, Volume 62, Supplement_1.
Published Ahead of Print - The Journal of Nuclear Medicine
WEBThe Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and ...
Procedure Guideline for Therapy of Thyroid Disease with
WEBJun 1, 2002 · Definitions. 131 Iodine is a β-emitting radionuclide with a physical half-life of 8.1 d, a principal γ-ray of 364 KeV, and a principal β-particle with a maximum energy of 0.61 MeV, an average energy of 0.192 MeV, and a range in tissue of 0.8 mm.. Therapy means the oral administration of 131 I as sodium iodide.. Benign conditions include Graves’ disease (toxic diffuse goiter), toxic or ...
18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: …
WEBJun 1, 2022 · Since the invention of 18F-FDG as a neurochemical tracer in the 1970s, 18F-FDG PET has been used extensively for dementia research and clinical applications. FDG, a glucose analog, is transported into the brain via glucose transporters and metabolized in a concerted process involving astrocytes and neurons. Although the exact cellular mechanisms of glucose consumption are still under ...
Physiological and Normal Variations in FDG uptake: A pictorial …
WEBMay 1, 2017 · 980 Objectives: 18-F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) scan, now considered the cornerstone of oncologic imaging requires knowledge of the normal patterns and variations in FDG distribution in the whole body. We aim to evaluate organ wise spectrum of distribution patterns, intensities and variations in normal physiological FDG uptake routinely ...
[177Lu]Lu-Prostate-Specific Membrane Antigen-617 in a Patient …
WEBSep 1, 2024 · In a 79-y-old man with metastatic castration-resistant prostate cancer and a history of bilateral nephrectomy for renal cell carcinoma, undergoing thrice-weekly hemodialysis, [68 Ga]Ga-PSMA-11 PET revealed intense prostate-specific membrane antigen–avid lesions ().He received 2 cycles of [177 Lu]Lu-PSMA-617, with a 60% dose reduction to 3.1 GBq (40% of the standard dose) in each cycle ().
JNM Information for Authors | Journal of Nuclear Medicine
WEBThe Journal of Nuclear Medicine (JNM) publishes material of interest to practitioners and scientists in the fields of nuclear medicine and molecular imaging. Proffered articles describing original laboratory or clinical investigations, brief communications, and letters to the editor will be considered for publication.
Current Concepts in Lymph Node Imaging - Journal of Nuclear …
WEBSep 1, 2004 · The accurate identification and characterization of lymph nodes by imaging has important therapeutic and prognostic significance in patients with newly diagnosed cancers. The presence of nodal metastases limits the therapeutic options and also generally indicates worse prognosis in patients. Thus, it becomes crucial to have this information before commencing therapy. Current cross-sectional ...
Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
WEBIII. EXAMPLES OF CLINICAL OR RESEARCH APPLICATIONS. Indications for 18 F-FDG PET/CT include but are not limited to the following:. Differentiating benign from malignant lesions. Searching for an unknown primary tumor when metastatic disease is discovered as the first manifestation of cancer or when the patient presents with a …